HDL Function as a Biomarker for Atherosclerotic Risk in Rheumatoid Arthritis

HDL 作为类风湿性关节炎动脉粥样硬化风险生物标志物的功能

• 批准号: 7922668
• 负责人: Christina Charles-Schoeman
• 金额: $ 13.78万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7922668
• 关键词: Accounting; Acute-Phase Proteins; Anti-Inflammatory Agents; Anti-inflammatory; Apolipoprotein A-I; Area; Arterial Fatty Streak; Arteries; Arthritis; Atherosclerosis; Biological Markers; Biometry; California; Cardiovascular Diseases; Cardiovascular system; Cell Wall; Characteristics; Cholesterol; Chronic; Clinical Research; Clinical Sciences; Clinical Trials; Coronary; Coronary heart disease; Development; Disease; Epidemiologic Studies; Epidemiology; Event; Fellowship; Functional disorder; General Population; Haptoglobins; Hemoglobin; Hemopexin; High Density Lipoprotein Cholesterol; High Density Lipoproteins; Inflammation; Inflammatory; Instruction; Investigation; Laboratory Research; Lipoproteins; Los Angeles; Low Density Lipoprotein oxidation; Low-Density Lipoproteins; Master' s Degree; Mentors; Morbidity - disease rate; Myocardial Infarction; Nature; Outcome; Patients; Peptides; Peroxidases; Phosphatidylcholine-Sterol O-Acyltransferase; Platelet Activating Factor; Population; Population Control; Principal Investigator; Program Development; Property; Proteins; Research; Research Methodology; Research Personnel; Rheumatoid Arthritis; Rheumatology; Risk; Risk Factors; Role; Serum amyloid A protein; Severities; Severity of illness; Thick; Training; Training Programs; Universities; Woman; Work; abstracting; cardiovascular disorder risk; cardiovascular risk factor; career; cohort; disorder control; high density lipoprotein-1; high risk; improved; insight; mimetics; mortality; oxidation; premature atherosclerosis; prevent; protective effect; skills; sulfated glycoprotein 2

DESCRIPTION (provided by applicant): This proposal describes a 5 year training program for the development of an academic career in rheumatology. The principal investigator has completed formal fellowship training in rheumatology at the University of California in Los Angeles (UCLA) and is currently finishing work for a master's degree in clinical research methodology. This unique, interdisciplinary training program will build upon the candidate's clinical science background, expanding her skills in areas of laboratory research, biostatistics, and epidemiology in order for successful development as an independent translational researcher. Dr. Srinivasa T. Reddy, co-director of the Center for Biomarker Discovery at UCLA and a recognized leader in atherosclerosis and lipoprotein research, and Dr. Daniel E. Furst, director of the Rheumatology Clinical Trials Center at UCLA and an expert in clinical investigation, will co-mentor the principal investigator's scientific development. Research will focus on the functional role of lipoproteins in inflammation and premature atherosclerosis in patients with rheumatoid arthritis (RA). Work in Dr. Reddy's lab has suggested that the anti- or pro-inflammatory nature of HDL function is a more sensitive indicator of atherosclerosis than standard HDL cholesterol levels. Abnormal, pro-inflammatory HDL is more common in RA patients than healthy controls and recent work by the candidate suggests that it is associated with increased disease severity, activity, and increased haptoglobin in HDL. Specific aims include: 1) To determine whether abnormal HDL anti-inflammatory function contributes to Increased atherosclerosis in patients with RA by examining its association with carotid intima wall thickness and plaque in a cohort of 240 RA patients. 2)To determine whether specific protein components of HDL are associated with a) abnormal HDL function, b) atherosclerosis, and c) disease activity in RA. 3) To determine the cumulative effects of RA disease activity on HDL function and HDL-associated proteins in a cross sectional RA cohort followed for three years. RELEVANCE (See instructions^: Identification of biomarkers that indicate a mechanism for early atherosclerosis in patients with RA is an important step in preventing morbidity from cardiovascular disease (CVD) in this population. Characterization of HDL dysfunction may further our understanding of why RA patients are at increased risk for CVD, and may also guide us in the development of new strategies to significantly impact CV morbidity and mortality. (End of Abstract)

描述（由申请人提供）：本提案描述了一个5年的培训计划，为发展风湿病学的学术生涯。主要研究者已在洛杉矶的加州大学（UCLA）完成了风湿病学的正式奖学金培训，目前正在完成临床研究方法学硕士学位的工作。这个独特的跨学科培训计划将建立在候选人的临床科学背景，扩大她在实验室研究，生物统计学和流行病学领域的技能，以便成功发展为独立的翻译研究人员。Dr. Srinivasa T.加州大学洛杉矶分校生物标志物发现中心的联合主任、动脉粥样硬化和脂蛋白研究领域公认的领导者Reddy博士和丹尼尔E。弗斯特是加州大学洛杉矶分校流变学临床试验中心主任，也是临床研究专家，他将共同指导主要研究者的科学发展。研究将集中于脂蛋白在类风湿关节炎（RA）患者炎症和过早动脉粥样硬化中的功能作用。Reddy博士实验室的工作表明，HDL功能的抗炎或促炎性质是比标准HDL胆固醇水平更敏感的动脉粥样硬化指标。异常的促炎性HDL在RA患者中比健康对照组更常见，候选人最近的工作表明，它与疾病严重程度增加，活动性增加和HDL中结合珠蛋白增加有关。具体目标包括：1）通过检测240例RA患者的颈动脉内膜厚度和斑块，确定异常HDL抗炎功能是否有助于RA患者动脉粥样硬化的增加。2）确定HDL的特定蛋白组分是否与a）HDL功能异常，B）动脉粥样硬化和c）RA的疾病活动性相关。3)确定RA疾病活动对HDL功能和HDL相关蛋白的累积影响，在一个随访3年的横断面RA队列中。相关性（参见说明^：鉴定表明RA患者早期动脉粥样硬化机制的生物标志物是预防该人群心血管疾病（CVD）发病的重要一步。HDL功能障碍的表征可能会进一步加深我们对RA患者CVD风险增加的原因的理解，也可能指导我们制定新的策略来显著影响CV发病率和死亡率。 (End摘要）